Advertisement

Topics

Gr8 news for patients and @InterceptPharma! Also, as first positive P3 study in NASH, this will facilitate wave of new Rx! https://www.statnews.com/2019/02/19/with-nash-results-intercept-pharma-will-seek-approval-for-first-ever-treatment-for-fatty-liver-c

08:39 EST 19 Feb 2019 | Brad Loncar

Gr8 news for patients and ! Also, as first positive P3 study in NASH, this will facilitate wave of new Rx! https://www.statnews.com/2019/02/19/with-nash-results-intercept-pharma-will-seek-approval-for-first-ever-treatment-for-fatty-liver-condition/ …

Original Article: Gr8 news for patients and @InterceptPharma! Also, as first positive P3 study in NASH, this will facilitate wave of new Rx! https://www.statnews.com/2019/02/19/with-nash-results-intercept-pharma-will-seek-approval-for-first-ever-treatment-for-fatty-liver-c

NEXT ARTICLE

More From BioPortfolio on "Gr8 news for patients and @InterceptPharma! Also, as first positive P3 study in NASH, this will facilitate wave of new Rx! https://www.statnews.com/2019/02/19/with-nash-results-intercept-pharma-will-seek-approval-for-first-ever-treatment-for-fatty-liver-c"

Advertisement
Quick Search
Advertisement
Advertisement